Atlihan-Gundogdu, EvrenEkinci, MelihaOzgenc, EmreDemir, Emine SelinIlem-Ozdemir, Derya2023-01-122023-01-1220222630-63442630-6344https://doi.org/10.29228/jrp.106https://hdl.handle.net/11454/78351In this study, we aimed to develop new lipid based nanoparticles (LPNs) and radiolabeled LPNs with [Tc-99m]Tc-HMPAO to investigate its cell binding capacity comparatively with [Tc-99m]Tc-HMPAO on different cancer cells. According to obtained results, LPNs with zeta potential of -27.4 +/- 0.95 mV, particle size of 93.5 +/- 1.17 nm, and polydispersity index of 0.35 +/- 0.04 were successfully developed. The optimum radiolabeling efficiency was found to be above 90% at 15-min of incubation time. The cell binding capacity of [Tc-99m]Tc-HMPAO-LPNs was found to be higher than [Tc-99m]Tc-HIYIPAO in cancer cell lines. The results demonstrated that [Tc-99m]Tc-HMPAO-LPNs may be a promising agent for cancer diagnosis alternatively to [Tc-99m]Tc-HMPAO.en10.29228/jrp.106info:eu-repo/semantics/openAccessLipid nanoparticlesradiopharmaceuticalsHMPAOcell bindingcancer diagnosisChitosan NanoparticlesIn-VitroFormulationCarriersArticle26188101WOS:0007382591000102-s2.0-85126925154Q3N/A